Resistance against novel anticancer metal compounds: differences and similarities.
about
Advances in drug delivery system for platinum agents based combination therapyUrinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugsMagnesium, zinc, arsenic, selenium and platinum urinary excretion from cancer patients of Antofagasta region, Chile: multi-metal approachCurcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatmentEndoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin-resistant cellsAnticancer activity of methyl-substituted oxaliplatin analogs.Genetic basis of arsenite and cadmium tolerance in Saccharomyces cerevisiae.Ruthenium-based chemotherapeutics: are they ready for prime time?Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics.Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazonesRetained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivoDiscovery of 'click' 1,2,3-triazolium salts as potential anticancer drugs.Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells.Anticancer activity of metal complexes: involvement of redox processes.Chemistry and biological activity of platinum amidine complexes.Targeting and delivery of platinum-based anticancer drugs.Metal complex interactions with DNA.New Look on 3-Hydroxyiminoflavanone and Its Palladium(II) Complex: Crystallographic and Spectroscopic Studies, Theoretical Calculations and Cytotoxic Activity.Preparation and Biological Evaluation of Two Novel Platinum(II) Complexes Based on the Ligands of Dipicolyamine Bisphosphonate Esters.O(6) -methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma.Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.trans-Platinum(II) complex of 3-aminoflavone - synthesis, X-ray crystal structure and biological activities in vitro.Differential growth inhibition of cancer cell lines and antioxidant activity of extracts of red, brown, and green marine algae.Saponins extracted from by-product of Asparagus officinalis L. suppress tumour cell migration and invasion through targeting Rho GTPase signalling pathway.Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery.Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity.Ruthenium(II/III)-based compounds with encouraging antiproliferative activity against non-small-cell lung cancer.[Zn(phen)(O,N,O)(H2O)] and [Zn(phen)(O,N)(H2O)] with O,N,O is 2,6-dipicolinate and N,O is L-threoninate: synthesis, characterization, and biomedical properties.Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds.Promising anticancer mono- and dinuclear ruthenium(III) dithiocarbamato complexes: systematic solution studies.Mono-carboxylated diaminedichloridoplatinum(IV) complexes--selective synthesis, characterization, and cytotoxicity.Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes.Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator.In vitro pharmacological study of monomeric platinum(III) hematoporphyrin IX complexes.Anticancer activity of a chelating nitrogen mustard bearing tetrachloridoplatinum(iv) complex: better stability yet equipotent to the Pt(ii) analogue.Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes.Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
P2860
Q26771390-F9BD8CEE-FABF-48EA-B71C-6F973E219365Q28388226-7C25C5F9-2BA2-4D63-9982-015EF9347CD4Q28391017-A6A2554E-D8A1-4622-8AEB-ED1628F4B736Q28393316-D148D806-8C23-435F-B87B-598B7E6C497CQ28533746-B65373A5-BB20-450A-A963-8C2F672E8DB5Q30515979-D0B4F7BE-E3EA-485C-9A01-81145F705131Q33417918-8F6CD386-7974-4DC7-8AC0-CED865F27336Q34102818-94C2B51F-633C-44E1-89B3-6CDEF6CFA6A7Q35154374-D82CD9CB-8633-4039-9285-FB461E4F1EC2Q35806000-90F8D123-F039-4984-9AFE-E2A1A5202A01Q35928856-F484C48D-FB50-486E-8640-E84A563C1C96Q36920272-89149856-C8AE-4413-85AD-D0F94B82C5E1Q37142916-49AE6155-7146-450F-B159-2148D254F504Q37253610-530B9CF4-DB43-4D5A-A618-8438938DCBDDQ37258715-E4B60952-1662-4097-8BCA-DAD15E7BCFEAQ37317264-35E8AAB7-2585-469D-9E6A-8DDC6A79ADEBQ37833099-1C5293AD-69EC-4946-926C-DD04D492182AQ37883259-1BB5AB8F-C924-4896-9AFE-9CA72ECE92AFQ38050063-3AF653E2-0993-4EBF-8539-CA3A199EBA51Q38271731-5EE0F6CA-59FD-4A7F-AA4A-31DB1ECE3DEFQ38777400-8720AB46-0CC1-4C23-9ACB-32BAF2C5D3C3Q38790152-D2FB7597-BB21-4DDE-BEBA-4BF957BB9A84Q38908320-A01542FC-92E3-432E-A7F3-FB9DEE2D714AQ38942848-2B52C883-DCEA-4629-A18B-976489311AEBQ38967226-F9D154E7-39E7-4FAA-B9F1-FA94C42A4F1CQ39156082-47F8A485-B5B5-4C68-BCD5-3F5A0901B2B7Q39186983-772F5F6B-42CC-4A5B-B2E8-4710569BEEE7Q39196999-740777E4-2411-4A7B-8FD5-97E6ECF6D4F4Q39235908-98D2AE89-5CB8-4FE4-92F0-75A2206086AAQ39271352-9CD1C336-CF41-4737-8F3D-572BDED3D194Q39309334-6B47131D-FBB5-454B-9AAF-F6DC2B401D77Q39415554-93BCB493-B2CD-4E02-94F8-36DDDE204A23Q39463198-F1C5CB27-79D4-43FE-A681-D3BC84CADE62Q39509386-C451DC31-3EC4-46C0-A1C5-5EB92210EEB2Q39625764-E44AB642-17E4-483E-8764-46CB5D385924Q39695089-9E932DFF-35DA-428B-A643-169900536D08Q39728594-31B11E75-F616-4E25-AD2C-6AED88998FEDQ39732972-8BF60D0D-EDDA-4A6E-AAB7-63B871B5F53FQ39773916-1F87C8CD-4368-4FC0-B215-719A6DC4DC3BQ39788647-0481AC7E-F00C-4A74-A788-E275FC12377B
P2860
Resistance against novel anticancer metal compounds: differences and similarities.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Resistance against novel anticancer metal compounds: differences and similarities.
@en
Resistance against novel anticancer metal compounds: differences and similarities.
@nl
type
label
Resistance against novel anticancer metal compounds: differences and similarities.
@en
Resistance against novel anticancer metal compounds: differences and similarities.
@nl
prefLabel
Resistance against novel anticancer metal compounds: differences and similarities.
@en
Resistance against novel anticancer metal compounds: differences and similarities.
@nl
P2093
P50
P1476
Resistance against novel anticancer metal compounds: differences and similarities.
@en
P2093
Leonilla Elbling
Markus Galanski
Michael Micksche
P356
10.1016/J.DRUP.2008.02.002
P577
2008-02-01T00:00:00Z